Parenteral formulations of dopamine agonists
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
1. A method for treatment of a metabolic disorder selected from the group consisting of prediabetes and obesity, comprising:
parenterally administering to a subject in need of such treatment a parenteral dosage form comprising
(a) 2-bromo-a-ergocriptine (bromocriptine)
(b) a pharmaceutically acceptable permeation enhancer,
(c) a pharmaceutically acceptable solubility enhancer and
(d) a pharmaceutically acceptable bioadhesion enhancer,
once daily at a predetermined time and formulated to increase the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in said subject at a time corresponding to the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject,
said parenteral dosage form comprising an amount of said bromocriptine effective to treat said metabolic disorder in said subject,
said amount being less than the minimum amount of said bromocriptine that is effective to treat said metabolic disorder when said bromocriptine is administered orally to said subject, and
wherein said administration of said dosage form provides greater therapeutic effectiveness in treating said metabolic disorder compared to equi-molar circulating concentrations in the blood of the orally administered bromocriptine.
2. The method of claim 1 wherein said administration of said parenteral dosage form containing said bromocriptine to said subject provides an improved therapeutic index, compared to said oral administration.
3. The method of claim 1 wherein said bromocriptine is administered transmucosally.
4. The method of claim 1 wherein said bromocriptine is administered non-orally to said subject in an amount below the minimum amount required to treat said metabolic disorder or key element thereof when said bromocriptine is administered orally to said subject.
5. The method of claim 1 wherein said parenteral administration comprises sub-lingual administration.
6. The method of claim 1 wherein said reduced side effects are gastrointestinal side effects.
7. The method of claim 1 wherein said administering of said dosage form results in reduced amounts of bromocriptine active metabolites in the blood, compared to the level of active bromocriptine metabolites obtained when said bromocriptine is administered orally to said subject.
8. The method of claim 1 wherein said pre-determined time of day is at about the natural daily peak in the circadian rhythm of said central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject in need of said treatment.
9. The method of claim 1 wherein the parenteral dosage form is administered as a single daily dose comprising a total of about 0.02 to about 5.0 mg dopamine agonist.
10. The method of claim 1 wherein the parenteral dosage form is administered from about 0400 to about 1200 hours.
11. The method of claim 1 wherein administration of said parenteral dosage form provides a pharmacokinetic (PK) profile comprising a Cmax of 25-400 pg/ml for said dopamine agonist.
12. The method of claim 1 wherein upon administration to said subject said dosage form exhibits a pharmacokinetic (PK) profile comprising: a Tmax at about 1 to about 90 minutes after administration followed by a plasma drug concentration of at least 50% Cmax for a duration of about 90 to about 360 minutes.
13. The method of claim 11 wherein upon administration to said subject said dosage form exhibits a PK profile wherein at least about 90% of the bromocriptine is cleared from plasma within about 240 to about 480 minutes of said post-Cmax plasma drug concentration.
14. The method of claim 11 wherein upon administration to said subject said dosage form exhibits a PK profile wherein said Tmax is about 5 to about 90 minutes after administration of the dosage form followed by a post-Cmax level comprising about one-half Cmax within about 30 to about 150 minutes of Tmax.
15. The method of claim 11 wherein upon administration to said subject said dosage form exhibits a PK profile wherein said Tmax is about 5 to about 90 minutes after administration of the dosage form and is followed by a post-Cmax level comprising about one-half Cmax within about 90 to about 360 minutes of Tmax.
16. A method for treating a metabolic disorder selected from the group consisting of prediabetes and obesity which comprises: administering to a subject in need of such treatment a parenteral dosage form comprising 2-bromo-a-ergocriptine (bromocriptine), a pharmaceutically acceptable permeation enhancer, a pharmaceutically acceptable solubility enhancer and a pharmaceutically acceptable bioadhesion enhancer; the parenteral dosage form having an improved therapeutic index relative to an oral dosage form of said dopamine agonist, the parenteral dosage form being administered to a subject in need of such treatment once-daily at a time that increases the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in said subject at a time corresponding to the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject; said parenteral dosage form comprising a dose of said bromocriptine that results in a therapeutic plasma concentration of said bromocriptine upon administration of said dosage form to said subject, said dose being less than an equally therapeutically effective dose of said dopamine agonist when said bromocriptine is administered orally; and wherein, relative to oral administration of said bromocriptine in an amount that yields an equivalent or lesser Cmax level of said orally administered bromocriptine, administration of said parenteral dosage form results in
(i) improved efficacy of treating said metabolic disorder,
(ii) reduced side effects,
(iii) improved re-setting of daily plasma prolactin circadian rhythm,
(iv) reduced circulating metabolites and
(v) said dosage form exhibiting on administration to said subject a pharmacokinetic (PK) profile comprising: a Tmax at about 1 to about 90 minutes after administration; followed by a plasma drug concentration of at least 50% Cmax for a duration of about 90 to about 360 minutes, and at least the same level of said bromocriptine in the blood circulation of the subject as administration of the minimum amount of said bromocriptine that is effective to treat said metabolic disorder via the oral route, and said parenteral dosage has greater therapeutic effectiveness in treating said metabolic disorder compared to equimolar circulating concentrations in the blood of the orally administered bromocriptine.
17. The method of claim 16 wherein the parental dosage form comprises about 0.02 to about 5.0 mg of said dopamine agonist.
18. A method for treating a metabolic disorder selected from the group consisting of prediabetes and obesity which comprises: parenterally administering in the form of sublingual dosage to a subject in need of treatment of said metabolic disorder, a formulation containing 2-bromo-a-ergocriptine (bromocriptine), a pharmaceutically acceptable permeation enhancer, a pharmaceutically acceptable solubility enhancer and a pharmaceutically acceptable bioadhesion enhancer once daily at a predetermined time and formulated to increase the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in said subject at a time corresponding to the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject, said bromocriptine being administered in an amount that is less than the minimum amount of said bromocriptine effective to treat said metabolic disorder when said bromocriptine is administered orally, wherein said administration of said bromocriptine to said subject provides at least the same level of bromocriptine in the circulation of the subject as administration of the minimum amount of said bromocriptine that is effective to treat said metabolic disorder via the oral route and has greater therapeutic effectiveness in treating said metabolic disorder compared to equi-molar circulating concentrations in the blood of the orally administered bromocriptine.
19. The method of claim 18 wherein said bromocriptine is administered from about 0400 to about 1200 hours.
20. A method for treatment of a metabolic disorder selected from the group consisting of prediabetes and obesity comprising:
administering to a subject in need of such treatment a parenteral dosage form comprising 2-bromo-a-ergocriptine (bromocriptine), a pharmaceutically acceptable permeation enhancer, a pharmaceutically acceptable solubility enhancer and a pharmaceutically acceptable bioadhesion enhancer formulated to increase the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in said subject at a time corresponding to the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject,
said parenteral dosage form comprising an amount of said bromocriptine bromocriptine effective to treat said metabolic disorder when said bromocriptine is administered orally,
and wherein said administration of said parenteral dosage form leads to
(i) reduced side effects compared to oral administration of said bromocriptine in an amount sufficient to achieve the same blood concentration of said parenterally administered bromocriptine or
(ii) a lower amount of said parenterally administered bromocriptine in the circulation of the subject compared to administration of the minimum amount of said bromocriptine that is effective to treat said metabolic disorder via the oral route, and has greater therapeutic effectiveness in treating said metabolic disorder compared to or equi-A molar circulating blood concentrations of the orally administered bromocriptine.
21. Method for treatment of a metabolic disorder selected from the group consisting of prediabetes, and obesity comprising:
parenterally administering to a subject in need of such treatment a parenteral dosage form comprising 2-bromo-a-ergocriptine (bromocriptine) a pharmaceutically acceptable permeation enhancer, a pharmaceutically acceptable solubility enhancer and a pharmaceutically acceptable bioadhesion enhancer once daily at a predetermined time and formulated to increase the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in said subject at a time corresponding to the natural daily peak in the circadian rhythm of central dopaminergic neuronal activity in healthy individuals of the same species and sex as said subject,
said parenteral dosage form comprising an amount of said bromocriptine effective to treat said metabolic disorder in said subject,
said amount being less than the minimum amount of said bromocriptine that is effective to treat said metabolic disorder when said bromocriptine is administered orally to said subject, and wherein said administration of said dosage form provides at least the same level of bromocriptine in the circulation of the subject as administration of the minimum amount of said bromocriptine that is effective to treat said metabolic disorder via the oral route and has greater therapeutic effectiveness in treating said metabolic disorder, compared to equimolar circulating concentrations in the blood of the A orally administered bromocriptine.